Back to results
US 2014/0212972 A1Published application
Process for producing cytotoxic lymphocyte
AssigneeTakara Bio Inc.
InventorsHiroaki SAGAWA, Mitsuko IDENO, lkunoshin KATO
Life of this patent
Estimating the term…
Abstract
The present invention relates to a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one of induction, maintenance and expansion of a cytotoxic lymphocyte in the presence of fibronectin, a fragment thereof or a mixture thereof.
Claims10
A method for expanding cytotoxic lymphocytes which comprises:
- culturing precursor cells, capable of differentiating to cytotoxic lymphocytes, wherein the precursor cells are selected from the group consisting of peripheral blood mononuclear cells and blood components containing these cells in the presence of at least one recombinant fibronectin fragment together with interleukin-2 and an anti-CD3 antibody,
- wherein the recombinant fibronectin fragment is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 8 to 19,
- wherein the expanded cytotoxic lymphocytes maintain cytotoxic activity longer than cytotoxic lymphocytes expanded in the absence of at least one fibronectin fragment, and
- wherein the expanded cytotoxic lymphocytes express more CD8 than cytotoxic lymphocytes expanded in the absence of at least one fibronectin fragment.
2 more elements
A method for increasing the number of CD8 positive cells in a population of cytotoxic lymphocytes, which comprises:
- culturing precursor cells, capable of differentiating to cytotoxic lymphocytes, wherein the precursor cells are selected from the group consisting of peripheral blood mononuclear cells and blood components containing these cells in the presence of at least one recombinant fibronectin fragment together with interleukin-2 and an anti-CD3 antibody, thereby increasing the number of CD8-positive cells in the cultured cells,
- wherein the recombinant fibronectin fragment is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS:
- 8 to 19,
- wherein the cultured cytotoxic lymphocytes maintain cytotoxic activity longer than cytotoxic lymphocytes expanded in the absence of at least one recombinant fibronectin fragment.
1 more element
Dependencies are inferred from the claim text.